LU91655I2 - Corifollitropine alfa et ses dérivés pharmaceutiquement acceptables (ELONVA®) - Google Patents

Corifollitropine alfa et ses dérivés pharmaceutiquement acceptables (ELONVA®)

Info

Publication number
LU91655I2
LU91655I2 LU91655C LU91655C LU91655I2 LU 91655 I2 LU91655 I2 LU 91655I2 LU 91655 C LU91655 C LU 91655C LU 91655 C LU91655 C LU 91655C LU 91655 I2 LU91655 I2 LU 91655I2
Authority
LU
Luxembourg
Prior art keywords
elonva
pharmaceutically acceptable
acceptable derivatives
corifollitropin alfa
corifollitropin
Prior art date
Application number
LU91655C
Other languages
English (en)
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of LU91655I2 publication Critical patent/LU91655I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LU91655C 1997-01-15 2010-02-24 Corifollitropine alfa et ses dérivés pharmaceutiquement acceptables (ELONVA®) LU91655I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97200099 1997-01-15
EP98200068A EP0853945B1 (fr) 1997-01-15 1998-01-13 Formulations liquides contenant une gonadotropine

Publications (1)

Publication Number Publication Date
LU91655I2 true LU91655I2 (fr) 2010-04-26

Family

ID=8227932

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91655C LU91655I2 (fr) 1997-01-15 2010-02-24 Corifollitropine alfa et ses dérivés pharmaceutiquement acceptables (ELONVA®)

Country Status (30)

Country Link
US (1) US5929028A (fr)
EP (2) EP1285665A1 (fr)
JP (1) JP4353549B2 (fr)
KR (1) KR100498531B1 (fr)
CN (1) CN1165341C (fr)
AR (1) AR011410A1 (fr)
AT (1) ATE237348T1 (fr)
AU (1) AU736339B2 (fr)
BR (1) BR9800323B1 (fr)
CA (1) CA2226803A1 (fr)
CZ (1) CZ297419B6 (fr)
DE (2) DE69813322T2 (fr)
DK (1) DK0853945T3 (fr)
ES (1) ES2196474T3 (fr)
FR (1) FR10C0024I2 (fr)
HK (1) HK1010150A1 (fr)
HU (1) HU227154B1 (fr)
ID (1) ID19499A (fr)
IL (1) IL122732A0 (fr)
LU (1) LU91655I2 (fr)
MX (1) MX9800438A (fr)
NO (3) NO322509B1 (fr)
NZ (1) NZ329572A (fr)
PL (1) PL190103B1 (fr)
PT (1) PT853945E (fr)
RU (1) RU2203086C2 (fr)
SA (1) SA98181124B1 (fr)
TR (1) TR199800062A2 (fr)
TW (1) TW518235B (fr)
ZA (1) ZA9883B (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010083126A (ko) * 1998-07-23 2001-08-31 피터 지. 스트링거 여포자극 호르몬 및 여포자극 호르몬 변이체 제형, 제품및 방법
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
JP2007204498A (ja) * 1999-03-01 2007-08-16 Chugai Pharmaceut Co Ltd 長期安定化製剤
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
CN1360506A (zh) * 1999-07-12 2002-07-24 格兰迪斯生物技术有限公司 生长激素配方
DK1261622T3 (da) * 2000-02-22 2007-05-29 Applied Research Systems Oprenset rekombinant hLH med en specifik bioaktivitet og fremgangsmåde til oprensning deraf
US7256184B2 (en) * 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
AU2007200662A1 (en) * 2001-08-30 2007-03-08 Kirin-Amgen, Inc. L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
EP1346843A1 (fr) * 2002-03-22 2003-09-24 Fuji Photo Film Co., Ltd. Procédé de formation d'images
NZ542549A (en) 2003-03-04 2008-11-28 Aspenbio Pharma Inc Methods and kits for maintaining pregnancy, treating follicular cysts, and synchronizing ovulation using single-chain luteinizing hormone
WO2004087213A1 (fr) * 2003-04-02 2004-10-14 Ares Trading S.A. Formulations pharmaceutiques fsh et lh
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
JP4871124B2 (ja) * 2003-06-20 2012-02-08 アレス トレーディング ソシエテ アノニム 凍結乾燥ｆｓｈ／ｌｈ製剤
JP4412989B2 (ja) * 2003-12-15 2010-02-10 株式会社日立製作所 複数の記憶システムを有するデータ処理システム
KR100587535B1 (ko) * 2004-02-04 2006-06-08 충남대학교산학협력단 재조합 ｈＦＳＨ 유전자 및 이를 내장하는 발현용 벡터
TWI369401B (en) * 2005-07-05 2012-08-01 Ares Trading Sa Serum-free culture medium for the production of recombinant gonadotropins
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
WO2007056851A1 (fr) * 2005-11-17 2007-05-24 Mount Sinai Hospital Compositions et procedes visant a ameliorer les agents inducteurs de l'ovulation
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8450269B2 (en) * 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
WO2008038817A1 (fr) * 2006-09-25 2008-04-03 National University Corporation Tokyo University Of Agriculture And Technology Dispositif de fonctionnement ultrasonique et système interne à microtube
KR20080106636A (ko) * 2007-06-04 2008-12-09 동아제약주식회사 사람 융모성 성선자극호르몬 함유 즉시 사용형 주사 용액
US7951368B2 (en) * 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
KR101522217B1 (ko) 2007-06-28 2015-05-21 바이오제너릭스 게엠베하 Ｆｓｈ 제조 세포 클론
NZ583991A (en) * 2007-11-01 2012-02-24 Merck Serono Sa Luteinizing hormone liquid formulations
NZ586588A (en) * 2008-02-08 2012-10-26 Biogenerix Ag Formulation of ( follice stimulating hormone) fsh and varients with benzalkonium chloride and benzyl alcohol
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
CN101347613B (zh) * 2008-09-17 2011-10-26 上海天伟生物制药有限公司 几乎不含亚基的糖蛋白的组合物及其制备方法
CN102309745B (zh) * 2008-09-17 2013-05-08 上海天伟生物制药有限公司 一种卵泡刺激素冻干针剂
AU2009312235B2 (en) 2008-11-04 2014-01-16 Aska Pharmaceutical Co., Ltd. Aqueous composition containing follicle-stimulating hormone
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
TWI604850B (zh) 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2325194A1 (fr) 2009-11-24 2011-05-25 Glycotope GmbH Processus de purification de glycoprotéines
EP2417982A1 (fr) * 2010-07-30 2012-02-15 Ferring B.V. Stabilisation de gonadotrophines
WO2012127501A2 (fr) * 2011-03-11 2012-09-27 Sanzyme Limited Composition pour améliorer l'épaisseur endométriale au cours de la stimulation ovarienne
WO2012127500A2 (fr) * 2011-03-11 2012-09-27 Sanzyme Limited Composition pour la spermatogenèse
JP6087338B2 (ja) 2011-03-31 2017-03-01 フェリング ベスローテン フェンノートシャップ 医薬製剤
US8680086B2 (en) 2011-04-15 2014-03-25 Neuralight Hd, Llc Methods for chronic pain management and treatment using HCG
US20120265129A1 (en) 2011-04-15 2012-10-18 Neuralight Hd, Llc Methods for Chronic Pain Management and Treatment using HCG
BR112014001274A2 (pt) 2011-07-18 2017-04-18 Arts Biologics As composto de hormônio luteinizante, e, composição farmacêutica
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
KR20150008137A (ko) 2012-04-19 2015-01-21 옵코 바이오로직스 리미티드 지속성 옥신토모둘린 변이체 및 이의 생산 방법
WO2014063071A1 (fr) 2012-10-18 2014-04-24 Neuralight Hd, Llc Traitement de la dépression et du tspt
HUE055348T2 (hu) 2012-11-20 2021-11-29 Opko Biologics Ltd Eljárás polipeptidek hidrodinamikus térfogatának növelésére gonadotropin karboxil-terminális peptidekhez való kapcsolással
CN105142656B (zh) 2013-03-12 2019-05-10 大日本住友制药株式会社 水性液体组合物
EP2968391A1 (fr) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Molécules polynucléotidiques à longue durée de vie
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3068374A1 (fr) 2013-11-12 2016-09-21 Cadila Healthcare Limited Formulation pour les gonadotrophines
DK3209319T3 (da) * 2014-10-21 2021-10-04 Hexima Ltd En fremgangsmåde til behandling af svampeinfektioner
EP3310347B1 (fr) 2015-06-19 2021-08-04 OPKO Biologics Ltd. Facteurs de coagulation à action prolongée et leurs procédés de production
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
IL264208B1 (en) 2016-07-11 2024-10-01 Opko Biologics Ltd Long-term coagulation factors and methods for their preparation
MX2019002835A (es) 2016-09-13 2019-09-04 Allergan Inc Composiciones no proteínicas de toxina clostridial.
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
WO2020229699A1 (fr) 2019-05-16 2020-11-19 Ceva Sante Animale Compositions et méthodes pour augmenter la performance de reproduction chez des mammifères non humains à l'aide d'une hormone lutéinisante recombinante
CN112451652A (zh) * 2020-12-07 2021-03-09 苏州智核生物医药科技有限公司 一种重组人促甲状腺素注射液
CN117783545A (zh) * 2023-12-28 2024-03-29 深圳市新产业生物医学工程股份有限公司 经封闭剂封闭的软质材料、容器、液态校准品及检测试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357934A (en) * 1980-07-23 1982-11-09 The Curators Of The University Of Missouri Method of treating male infertility
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
IT1206302B (it) * 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5338835A (en) * 1989-02-21 1994-08-16 Washington University CTP-extended form of FSH
DE69029799T2 (de) * 1989-02-21 1997-05-28 Washington University, St. Louis, Mo. Modifizierte formen von fortpflanzungshormonen
US5114948A (en) * 1989-10-19 1992-05-19 Eli Lilly And Company Stabilized pergolide compositions
US5384132A (en) * 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
ATE173739T1 (de) * 1992-04-30 1998-12-15 Cor Therapeutics Inc Stabile zusammensetzung von polypeptiden
US5281198A (en) * 1992-05-04 1994-01-25 Habley Medical Technology Corporation Pharmaceutical component-mixing delivery assembly
EP0814841B1 (fr) * 1995-03-21 2001-12-05 Applied Research Systems ARS Holding N.V. Compositions liquides de gonadotrophine chorionique de l'homme

Also Published As

Publication number Publication date
CZ297419B6 (cs) 2006-12-13
PL324279A1 (en) 1998-07-20
HU227154B1 (en) 2010-08-30
TW518235B (en) 2003-01-21
IL122732A0 (en) 1998-08-16
CN1165341C (zh) 2004-09-08
NO980177L (no) 1998-07-16
BR9800323A (pt) 1999-06-29
NO2010013I1 (no) 2010-06-07
CZ13598A3 (cs) 1998-08-12
ID19499A (id) 1998-07-16
KR19980070493A (ko) 1998-10-26
HK1010150A1 (en) 1999-06-17
EP0853945A1 (fr) 1998-07-22
CA2226803A1 (fr) 1998-07-15
JP4353549B2 (ja) 2009-10-28
ATE237348T1 (de) 2003-05-15
BR9800323B1 (pt) 2011-04-19
MX9800438A (es) 1998-11-30
HUP9800056A2 (hu) 1998-08-28
SA98181124B1 (ar) 2006-07-10
DE69813322T2 (de) 2004-02-19
FR10C0024I2 (fr) 2011-04-01
NO2021001I1 (no) 2021-01-12
HU9800056D0 (en) 1998-03-02
PL190103B1 (pl) 2005-10-31
DE122010000011I1 (de) 2010-07-08
EP0853945B1 (fr) 2003-04-16
HUP9800056A3 (en) 2001-01-29
ES2196474T3 (es) 2003-12-16
NO980177D0 (no) 1998-01-14
CN1191139A (zh) 1998-08-26
DK0853945T3 (da) 2003-08-04
FR10C0024I1 (fr) 2010-05-21
DE69813322D1 (de) 2003-05-22
NO322509B1 (no) 2006-10-16
PT853945E (pt) 2003-08-29
NO2010013I2 (no) 2015-05-18
NZ329572A (en) 1999-05-28
ZA9883B (en) 1998-07-08
AU736339B2 (en) 2001-07-26
EP1285665A1 (fr) 2003-02-26
AU5205998A (en) 1998-07-23
AR011410A1 (es) 2000-08-16
RU2203086C2 (ru) 2003-04-27
US5929028A (en) 1999-07-27
KR100498531B1 (ko) 2005-09-30
TR199800062A2 (xx) 1998-08-21
JPH10203997A (ja) 1998-08-04

Similar Documents

Publication Publication Date Title
LU91655I2 (fr) Corifollitropine alfa et ses dérivés pharmaceutiquement acceptables (ELONVA®)
LU91346I2 (fr) Lumiracoxib et ses dérivés pharmaceutiquement acceptables (prexige)
LU91122I2 (fr) Efalizumab et ses dérivés pharmaceutiquement acceptables (raptiva).
LU91673I2 (fr) "Dronédarone et ses dérivés pharmaceutiquement acceptables (MULTAQ)"
LU91138I2 (fr) Glulisine d'insuline et ses dérivés pharmaceutiquement acceptables.
LU92381I2 (fr) Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT)
LU91624I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®)
LU92024I2 (fr) Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR)
LU91189I2 (fr) Atazanavir sulphate et ses dérivés pharmaceutiquement acceptables (REYATAZ)
LU91076I2 (fr) Tulathromycin et ses sels pharmaceutiquement acceptables (draxxin).
LU92745I2 (fr) Nétupitant/Palonosétron et leurs dérivés pharmaceutiquement acceptables (AKYNZEOr)
LU91163I2 (fr) Hydrobromure de darifénacine et ses dérivés pharmaceutiquement acceptables (EMSELEX.
LU91269I2 (fr) Rotigotine et ses dérivés pharmaceutiquement acceptables (neupro)
DE69633991T2 (de) CMDA-Basisstaionssender
DK1005446T3 (da) N-aroylphenylalaninderivater
ATE235220T1 (de) Resorcinderivate
ID22781A (id) Turunan-turunan nikotinamida
LU91757I2 (fr) Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
DE69817186D1 (de) Diaminorhodamin-derivate
PL337773A1 (en) Derivatives of benzimidazoles
LU91849I2 (fr) Cimicoxib et ses dérivés pharmaceutiquement acceptables - CIMALGEX®.
DE59707194D1 (de) Direkttablettierhilfsmittel
PT1000048E (pt) Derivados substituidos do 1,2,3,4-tetrahidronaftaleno
DE19980536D2 (de) Vinylen- und Ethylverbindungen
DE69623090D1 (de) Bett